Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1768 • ACR Convergence 2020
The Importance of Pregnancy Planning in Lupus Pregnancies
Aardra Rajendran¹, Amanda Eudy², Stephen Balevic³ and Megan Clowse⁴, ¹Duke University, Lewisville, NC, ²Duke University, Durham, NC, ³Duke University, Hillsborough, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Given the clinical importance of the pre-conception period in lupus pregnancy management and because pregnancy planning can be potentially improved, this study explores the…
Abstract Number: 1798 • ACR Convergence 2020
IgE Anti-dsDNA Antibodies in Systemic Lupus Erythematosus Are Associated with Higher Disease Activity at the Baseline and in Longterm Follow-up
Omer Pamuk¹, Zerai Manna², Rutha Adhanom², Xiaobai Li³, Mariana Kaplan⁴ and Sarfaraz Hasni², ¹Rheumatology Fellowship and Training Branch, NIAMS/NIH, Bethesda, MD, ²Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, ³Biostatistics and Clinical Epidemiology Service, Clinical Center, NIH, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Recent reports indicate that autoreactive anti-dsDNA IgE autoantibodies and IgE immune complexes and can activate innate and adaptive immunity leading to amplification of lupus…
Abstract Number: 1816 • ACR Convergence 2020
Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis
Brianna Lally¹, Shudan Wang², Sammy Chalmers³, Wenzhu Mowrey³, Tamar Rubinstein⁴, Beatrice Goilav⁵ and Anna Broder⁶, ¹Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, New York, NY, ³Albert Einstein College of Medicine, Bronx, ⁴Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY, ⁵The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁶Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Tubulointerstitial disease (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy (IFTA), is associated with progression to end stage renal disease (ESRD) in…
Abstract Number: 1832 • ACR Convergence 2020
Barriers to Medication Adherence and Degree of Nonadherence in a Systemic Lupus Erythematosus Outpatient Population
Courtney Hardy¹, Dafna Gladman², Jiandong Su³, Nathalie Rozenbojm⁴ and Murray Urowitz⁵, ¹University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Toronto, ON, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: It has been reported that 50% to 75% of patients with SLE do not adhere to their medications. However, the reasons for nonadherence are not clear.…
Abstract Number: 1980 • ACR Convergence 2020
Understanding the Relationship Between Illness Perceptions and Self-Efficacy Among Latin Americans with SLE Through the Hablemos De Lupus Facebook Page
Erica Crosley¹, Claudia Elera-Fitzcarrald², Leandro Gabriel Ferreyra Garrot³, Yurilis Fuentes-Silva⁴, Soledad Ibañez⁵, Bernardo Pons-Estel⁶, Cristina Reátegui-Sokolova⁷ and Cristina Drenkard⁸, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Rheumatology. Hospital Nacional Guillermo Almenara Irigoyen. EsSalud; Universidad Científica del Sur, Lima, Peru, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Universidad de Oriente, Ciudad Bolívar, Venezuela, ⁵Sanatorio Güemes, Buenos Aires, Argentina, ⁶Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ⁷Hospital Guillermo Almenara Irigoyen; Universidad San Ignacio de Loyola, Lima, Peru, ⁸Division of Rheumatology, Department of Medicine, Emory School of Medicine, Atlanta, GA
Background/Purpose: SLE disproportionately strikes Latinos, who are also at high risk for poor outcomes. Self-efficacy (SE) to manage chronic disease correlates with outcomes through self-management…
Abstract Number: 0021 • ACR Convergence 2020
Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned
Dominique Kinnett-Hopkins¹, Linda Ehrlich-Jones², Holly Milaeger³, Alanna Kenney³, Lorena Rosiles³ and Rosalind Ramsey-Goldman⁴, ¹Northwestern University, Chicago, IL, ²Shirley Ryan AbilityLab, Chicago, ³Northwestern University, Chicago, ⁴Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The coronavirus disease 2019 (COVID-19) global pandemic has drastically impacted the health system and the research community. Many research institutions and funding agencies recommended…
Abstract Number: 0253 • ACR Convergence 2020
Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis
Tara Tofighi¹, Heather Reich², Jiandong Su³ and Zahi Touma⁴, ¹Department of Medicine, University of Toronto, Toronto, Canada, ²Division of Nephrology, University of Toronto, Toronto, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada
Background/Purpose: Clinical trials and observational studies in lupus nephritis (LN) have shown that proteinuria level at 12 months is the best predictor of long-term renal…
Abstract Number: 0270 • ACR Convergence 2020
The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE
Laura Whittall-Garcia¹, Dafna Gladman², Murray Urowitz³, Jiandong Su⁴ and Sindhu Johnson⁵, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: SLE is characterized by different patterns of disease activity throughout its course. Overall, a higher disease activity is an important predictor of mortality and…
Abstract Number: 0287 • ACR Convergence 2020
RNA Externalized by Neutrophil Extracellular Traps Promotes Inflammatory Pathways in Endothelial Cells
Xinghao Wang¹, Philip Carlucci², Jorge Romo-Tena¹, Jose Torres-Ruiz¹, Hong-Wei Sun¹, Markus Hafner¹, Mariana Kaplan³ and Luz Blanco⁴, ¹NIAMS, National Institute of Health, Bethesda, ²New York University School of Medicine, New York, NY, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Centreville
Background/Purpose: Neutrophil extracellular traps (NETs) are extracellular lattices composed of nucleic material bound to neutrophil granule proteins. NETs may play pathogenic roles in development and…
Abstract Number: 0304 • ACR Convergence 2020
Type I Interferon Inhibits Glucocorticoid-Induced Leucine Zipper (GILZ) Expression and Upregulation by Glucocorticoids
Wendy Dankers¹, Melissa Northcott², Taylah Bennett³, Brendan Russ³, Jacqueline Flynn¹, Sarah Jones² and Eric Morand¹, ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, ³Department of Microbiology, Monash University, Melbourne, Australia
Background/Purpose: Glucocorticoids (GC) are broadly used in the treatment of inflammatory diseases, including systemic lupus erythematosus (SLE). Despite their widespread use, most SLE patients do…
Abstract Number: 0521 • ACR Convergence 2020
Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?
Flavio Signorelli¹, Gustavo Balbi², Eloisa Bonfa³, Eduardo Borba⁴ and Danieli Andrade⁵, ¹Universidade de São Paulo, Rio de janeiro, Rio de Janeiro, Brazil, ²Universidade de São Paulo, Juiz de Fora, Minas Gerais, Brazil, ³Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Primary Antiphospholipid Syndrome (PAPS) patients, when submitted to Systemic Lupus Erythematosus (SLE) classification criteria, can be misclassified. The new 2019 ACR/EULAR classification criteria have…
Abstract Number: 0788 • ACR Convergence 2020
Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery
Wei Jiang¹, Alexander Alekseyenko², Gary Gilkeson³, Jim Oates⁴, Elizabeth Ogunrind⁵, Quan Li⁶, Diane Kamen², Betty Tsao⁵ and Zhenwu Luo⁵, ¹MUSC, Charleston, SC, ²Medical University of South Carolina, Charleston, SC, ³Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁴Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁵Medical University of South Carolina, Charleston, ⁶UT South Western Medical Center, Texas
Background/Purpose: The mucosal microbiome contributes to disease pathogenesis via local and systemic interaction with the host. The hallmark of this interaction in the physiological condition…
Abstract Number: 0854 • ACR Convergence 2020
Mortality and Adverse Events of Special Interest in Adult Patients with Systemic Lupus Erythematosus Receiving Intravenous Belimumab: A Post Hoc Descriptive Summary of Serious Psychiatric Events
Saira Sheikh¹, Ricardo Acayaba de Toledo², Laura Geraldino-Pardilla³, Julia Harris⁴, Regina Kurrasch⁵, Andrew Liu⁴, Kathleen Maksimowicz-McKinnon⁶, Holly Quasny⁷, David Roth⁵, Lilian Soto⁸ and Rajesh Punwaney⁵, ¹University of North Carolina Thurston Arthritis Research Center, Chapel Hill, ²Faculdade de Medicina de São José do Rio Preto, São Paulo, Brazil, ³Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, ⁴GlaxoSmithKline, Uxbridge, United Kingdom, ⁵GlaxoSmithKline, Collegeville, ⁶Henry Ford Hospital, Detroit, ⁷GlaxoSmithKline, Research Triangle Park, ⁸Facultad de Medicina, Clinical Hospital of Universidad de Chile, Santiago, Chile
Background/Purpose: Intravenous (IV) belimumab (BEL) is approved in patients ≥5 years of age with active systemic lupus erythematosus (SLE). Results of the BASE study (the…
Abstract Number: 0872 • ACR Convergence 2020
Usage of Corticosteroids and Hospitalisation Duration in Adult Patients with Systemic Lupus Erythematosus (SLE) in Latvia
Ilze Vinkalna¹, Inita Bulina², Natalija Vellere², Kristine Ivanova², Pauls Rubins², Renate Diura², Santa Mikena², Julija Zepa² and Daina Andersone², ¹Pauls Stradins Clinical University Hospital, Rīga, Latvia, ²Pauls Stradins Clinical University Hospital, Riga
Background/Purpose: To determine the factors influencing hospitalisation duration, re – hospitalisation (more than 1 hospitalisation during the study period), frequency of the usage of corticosteroids…
Abstract Number: 0989 • ACR Convergence 2020
Withdrawal of MMF Is Safe in Quiescent Renal and Non-Renal SLE: Results from a Multi-Center Randomized Trial
Eliza Chakravarty¹, Tammy Utset², Diane Kamen³, Gabriel Contreras⁴, W. Joseph McCune⁵, Kenneth Kalunian⁶, Cynthia Aranow⁷, Megan Clowse⁸, Elena Massarotti⁹, Ellen Goldmuntz¹⁰, Jessica Springer¹⁰, Lynette Keyes-Elstein¹¹, Bill Barry¹¹, Ashley Pinckney¹¹ and Judith James¹², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Chicago, Chicago, IN, ³Medical University of South Carolina, Charleston, SC, ⁴University of Miami Miller School of Medicine, Miami, ⁵University of Michigan, Ann Arbor, MI, ⁶University of California San Diego, La Jolla, CA, ⁷Feinstein Institutes for Medical Research, Manhasset, NY, ⁸Duke University, Chapel Hill, NC, ⁹Brigham and Women's hospital, Boston, MA, ¹⁰NIH/NIAID, Rockville, MD, ¹¹Rho, Durham, NC, ¹²Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Mycophenolate Mofetil (MMF) is standard of care therapy for long term treatment of lupus nephritis and other manifestations of SLE. However, it is associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].